Erlocip

Discount 5.00 usd
BRAND :  ERLOCIP PRICE :  250$ STRENGTH : 150 MG ACTIVE :  ERLOCIP-ERLOTINIB-150MG COMPANY NAME :  CIPLA TABLETS :  30 TABLETS read more

250.00 usd
255.00
- +
Share

DESCRIPTION :

WHAT IS ERLOCIP ?

ERLOCIP is a targeted therapy. Erlocip is classified as a epidermal growth factor receptor (EGFR) inhibitor - protein-tyrosine kinase inhibitor. It works by helping to stop cancer cells from growing.

MEDICINE USES :
Erlocip medicine is used for :

Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Erlocip works by slowing cancer cell growth. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

ERLOCIP COMMON SIDE EFFECTS :
Nausea, vomiting, loss of appetite, mouth sores, dry skin, eye dryness/irritation, or unusual eyelash growth may occur. Changes in diet such as eating several small meals or limiting activity may help lessen the chance of nausea. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Tell your doctor right away if any of these rare but very serious side effects occur: signs of kidney problems (such as change in the amount of urine), black stools, vomit that looks like coffee grounds, easy bleeding/bruising, stomach/abdominal pain, yellowing eyes or skin, dark urine, unusual fatigue, signs of infection (e.g., fever, chills, persistent sore throat), eye pain, vision changes.

This is not a complete list of possible side effects. 
    No comments yet
Write a comment
Your name
Your name
Captcha

Sale of day

Choice of buyers. Only popular options!Choice of buyers.
Only popular options!

view all
Abbott
Biocon
Cipla
Dr. Reddy’s
Eisai
Emcure
Hetero
Intas
MSD
Mylan
Natco
Novartis
Strides
Zydus
  • Children born with HIV
    Children born with HIV
    Children born with HIV accessing treatment, have no significant difference in their movement skills, social interaction, language skills or practical reasoning at age five compared to HIV-negative children, according to new research....